Entrada Therapeutics to Present at Upcoming Investor Conferences
12 October 2023 - 10:00PM
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage
biopharmaceutical company aiming to transform the lives of patients
by establishing intracellular Endosomal Escape Vehicle
(EEV™)-therapeutics as a new class of medicines, today announced it
will participate in the following two investor conferences:
William Blair's Innovator Series: Genetic
MedicinesNathan Dowden, Chief Operating Officer, will
participate on the Changing the Trajectory of Neuromuscular
Diseases: DMD and Beyond virtual panel on Monday, October 16, 2023
at 11:00 a.m. Eastern Time.
Evercore ISI 6th Annual HealthCONx
ConferenceDipal Doshi, President and Chief Executive
Officer, will participate in an in-person fireside chat on
Wednesday, November 29, 2023 at 3:50 p.m. Eastern Time in Miami,
FL.
A live webcast of the fireside chat at the Evercore ISI 6th
Annual HealthCONx Conference and a replay of the panel at William
Blair's Innovator Series: Genetic Medicines will be available on
the Investor Relations section of the Company’s website at
www.entradatx.com. The replay of the fireside chat will be
available on the Entrada website for 90 days and the replay of the
panel will be available for 7 days following the events.
About Entrada TherapeuticsEntrada Therapeutics
is a clinical-stage biopharmaceutical company aiming to transform
the lives of patients by establishing a new class of medicines,
Endosomal Escape Vehicle (EEV™)-therapeutics, to engage
intracellular targets that have long been considered inaccessible
and undruggable. The Company’s EEV therapeutics are designed to
enable the efficient intracellular delivery of a wide range of
therapeutics into a variety of organs and tissues, resulting in an
improved therapeutic index. Through its proprietary, highly
versatile and modular EEV platform, Entrada is building a robust
development portfolio of RNA-, antibody- and enzyme-based programs
for the potential treatment of neuromuscular, immunological, ocular
and metabolic diseases, among others. The Company’s lead
oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for
the potential treatment of people living with Duchenne who are exon
44 and 45 skipping amenable, respectively, as well as a partnered
candidate ENTR-701 targeting myotonic dystrophy type 1.
For more information about Entrada, please visit our
website, www.entradatx.com, and follow us
on LinkedIn.
Investor and Media ContactKarla MacDonaldChief
Corporate Affairs Officerkmacdonald@entradatx.com
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Apr 2024 to May 2024
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From May 2023 to May 2024